Cargando…

Personalised prevention of type 2 diabetes

It is well established from clinical trials that behavioural interventions can halve the risk of progression from prediabetes to type 2 diabetes but translating this evidence of efficacy into effective real-world interventions at scale is an ongoing challenge. A common suggestion is that future prev...

Descripción completa

Detalles Bibliográficos
Autor principal: Wareham, Nicholas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522721/
https://www.ncbi.nlm.nih.gov/pubmed/35916901
http://dx.doi.org/10.1007/s00125-022-05774-7
_version_ 1784800119330177024
author Wareham, Nicholas J.
author_facet Wareham, Nicholas J.
author_sort Wareham, Nicholas J.
collection PubMed
description It is well established from clinical trials that behavioural interventions can halve the risk of progression from prediabetes to type 2 diabetes but translating this evidence of efficacy into effective real-world interventions at scale is an ongoing challenge. A common suggestion is that future preventive interventions need to be more personalised in order to enhance effectiveness. This review evaluates the degree to which existing interventions are already personalised and outlines how greater personalisation could be achieved through better identification of those at high risk, division of type 2 diabetes into specific subgroups and, above all, more individualisation of the behavioural targets for preventive action. Approaches using more dynamic real-time data are in their scientific infancy. Although these approaches are promising they need longer-term evaluation against clinical outcomes. Whatever personalised preventive approaches for type 2 diabetes are developed in the future, they will need to be complementary to existing individual-level interventions that are being rolled out and that are demonstrably effective. They will also need to ideally synergise with, and at the very least not detract attention from, efforts to develop and implement strategies that impact on type 2 diabetes risk at the societal level. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-9522721
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-95227212022-10-01 Personalised prevention of type 2 diabetes Wareham, Nicholas J. Diabetologia Review It is well established from clinical trials that behavioural interventions can halve the risk of progression from prediabetes to type 2 diabetes but translating this evidence of efficacy into effective real-world interventions at scale is an ongoing challenge. A common suggestion is that future preventive interventions need to be more personalised in order to enhance effectiveness. This review evaluates the degree to which existing interventions are already personalised and outlines how greater personalisation could be achieved through better identification of those at high risk, division of type 2 diabetes into specific subgroups and, above all, more individualisation of the behavioural targets for preventive action. Approaches using more dynamic real-time data are in their scientific infancy. Although these approaches are promising they need longer-term evaluation against clinical outcomes. Whatever personalised preventive approaches for type 2 diabetes are developed in the future, they will need to be complementary to existing individual-level interventions that are being rolled out and that are demonstrably effective. They will also need to ideally synergise with, and at the very least not detract attention from, efforts to develop and implement strategies that impact on type 2 diabetes risk at the societal level. GRAPHICAL ABSTRACT: [Image: see text] Springer Berlin Heidelberg 2022-08-02 2022 /pmc/articles/PMC9522721/ /pubmed/35916901 http://dx.doi.org/10.1007/s00125-022-05774-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Wareham, Nicholas J.
Personalised prevention of type 2 diabetes
title Personalised prevention of type 2 diabetes
title_full Personalised prevention of type 2 diabetes
title_fullStr Personalised prevention of type 2 diabetes
title_full_unstemmed Personalised prevention of type 2 diabetes
title_short Personalised prevention of type 2 diabetes
title_sort personalised prevention of type 2 diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522721/
https://www.ncbi.nlm.nih.gov/pubmed/35916901
http://dx.doi.org/10.1007/s00125-022-05774-7
work_keys_str_mv AT warehamnicholasj personalisedpreventionoftype2diabetes